Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Silence Therapeutics (SLN) Operating Leases: 2023-2025

Historic Operating Leases for Silence Therapeutics (SLN) over the last 1 years, with Sep 2025 value amounting to $97,000.

  • Silence Therapeutics' Operating Leases was N/A to $97,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $97,000, marking a year-over-year change of. This contributed to the annual value of $118,000 for FY2023, which is N/A change from last year.
  • Latest data reveals that Silence Therapeutics reported Operating Leases of $97,000 as of Q3 2025, which was down 17.78% from $117,972 recorded in Q1 2024.
  • Over the past 5 years, Silence Therapeutics' Operating Leases peaked at $264,981 during Q1 2023, and registered a low of $97,000 during Q3 2025.
  • For the 3-year period, Silence Therapeutics' Operating Leases averaged around $158,347, with its median value being $131,201 (2023).
  • Data for Silence Therapeutics' Operating Leases shows a maximum YoY tumbled of 55.48% (in 2024) over the last 5 years.
  • Over the past 3 years, Silence Therapeutics' Operating Leases (Quarterly) stood at $118,000 in 2023, then crashed by 55.48% to $117,972 in 2024, then reached $97,000 in 2025.
  • Its Operating Leases stands at $97,000 for Q3 2025, versus $117,972 for Q1 2024 and $118,000 for Q4 2023.